Acadian Asset Management LLC Purchases 8,248 Shares of Sotera Health (NASDAQ:SHC)

Acadian Asset Management LLC lifted its position in Sotera Health (NASDAQ:SHC) by 728.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,381 shares of the company’s stock after purchasing an additional 8,248 shares during the quarter. Acadian Asset Management LLC’s holdings in Sotera Health were worth $111,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of SHC. CWM LLC grew its stake in shares of Sotera Health by 86.1% in the 2nd quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the period. Swiss National Bank grew its position in Sotera Health by 0.5% in the first quarter. Swiss National Bank now owns 195,900 shares of the company’s stock valued at $2,353,000 after acquiring an additional 1,000 shares during the period. TD Asset Management Inc raised its stake in Sotera Health by 1.5% during the second quarter. TD Asset Management Inc now owns 123,454 shares of the company’s stock worth $1,465,000 after acquiring an additional 1,800 shares in the last quarter. Securian Asset Management Inc. lifted its holdings in shares of Sotera Health by 23.0% during the first quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock valued at $122,000 after acquiring an additional 1,900 shares during the period. Finally, State of Alaska Department of Revenue boosted its stake in shares of Sotera Health by 20.6% in the 1st quarter. State of Alaska Department of Revenue now owns 13,490 shares of the company’s stock valued at $162,000 after purchasing an additional 2,300 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Sotera Health Trading Up 0.7 %

SHC opened at $16.66 on Friday. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The firm has a 50-day moving average price of $14.87 and a two-hundred day moving average price of $12.85. The stock has a market capitalization of $4.72 billion, a PE ratio of 87.68 and a beta of 2.07. The company has a current ratio of 2.93, a quick ratio of 2.59 and a debt-to-equity ratio of 5.46.

Sotera Health (NASDAQ:SHC) last posted its quarterly earnings data on Monday, August 5th. The company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.04. The firm had revenue of $277.00 million during the quarter, compared to analysts’ expectations of $266.45 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. Sotera Health’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.19 EPS. As a group, equities analysts anticipate that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 55.12% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

SHC has been the subject of several analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Barclays lifted their target price on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.70.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.